RCT: Efficacy and safety of Difelikefalin in patients with moderate to severe pruritus receiving hemodialysis.

Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial – JAMA Network Open

Commentary on Twitter

This RCT found difelikefalin, a κ-opioid receptor agonist, improved moderate to severe pruritus in Japanese hemodialysis patients. Difelikefalin is expected to be a new option for the treatment of uremic pruritus in patients with end stage kidney disease. https://t.co/cXqNx4QIaS pic.twitter.com/7QdA9GoLwN

— JAMA Network Open (@JAMANetworkOpen) May 5, 2022